FDA Adverse Event Injury Summary report: N

POWERLINK SYSTEM

MDR report key: 3222199 · Received July 12, 2013

Report

Report Number
2031527-2013-00165
Event Type
Injury
Date Received
July 12, 2013
Date of Event
June 17, 2013
Report Date
June 17, 2013
Manufacturer
ENDOLOGIX, INC.
Product Code
MIH
PMA / PMN Number
P040002
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE DEVICE REMAINS IMPLANTED IN THE PATIENT, HENCE NO DEVICE EVALUATION WAS PERFORMED. HOWEVER, COMPUTED TOMOGRAPHY IMAGING POST INDEX PROCEDURE WERE PROVIDED FOR CLINICAL ASSESSMENT. BASED ON THE REVIEW, THE REPORT OF DISTAL ENDOLEAK TYPE I WAS CONFIRMED IN THE LEFT ILIAC ARTERY. AVAILABLE IMAGING SHOWS TORTUOUS ANATOMY AND LEFT ILIAC CALCIFICATION. THE LIKELY CAUSE OF THE ENDOLEAK APPEARS TO BE RELATED TO THE VESSEL TORTUOSITY AND CALCIFICATION. REVIEW OF THE MANUFACTURING RECORDS DID NOT INDICATE THAT THE DEVICE MAY HAVE CAUSED OR CONTRIBUTED TO THE EVENT. ENDOLEAKS ARE A KNOWN RISK OF THE PROCEDURE, AND ARE IDENTIFIED IN THE PRODUCT LABELING UNDER POTENTIAL ADVERSE EVENTS.

Additional Manufacturer Narrative · 1

ENDOLOGIX CONTINUES TO INVESTIGATE THE REPORTED EVENT. ENDOLOGIX WILL SUBMIT A SUPPLEMENTAL REPORT IN ACCORDANCE WITH 21 CFR 803.56 WHEN ADDITIONAL INFORMATION BECOMES AVAILABLE. REMAINS IMPLANTED IN THE PATIENT.

Description of Event or Problem · 1

IT WAS REPORTED THAT APPROXIMATELY 2 MONTHS POST-IMPLANT OF A BIFURCATED DEVICE, A SUPRARENAL AORTIC EXTENSION AND TWO LIMB EXTENSIONS, A FOLLOW-UP COMPUTED TOMOGRAPHY SCAN REVEALED A DISTAL TYPE 1 ENDOLEAK ON THE LEFT LIMB. THE PATIENT WAS TREATED 3 MONTHS LATER WITH AN ADDITIONAL LIMB EXTENSION, WHICH SUCCESSFULLY CORRECTED THE ENDOLEAK. REPORTEDLY, THE PATIENT TOLERATED THE PROCEDURE WELL.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
324121 POWERLINK SYSTEM INFRARENAL BIFURCATED STENT GRAFT MIH ENDOLOGIX, INC. 28-16-140BL 1062538-002

Patients

Seq Age Sex Outcome Treatment
1 62 YR Required Intervention